CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma

Lupo, Kyle B.; Matosevic, Sandro

doi:10.1186/s13045-020-00913-2

Cited by 73 publications

(54 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TIGIT is an inhibitory checkpoint receptor that has become the focus of much research due to its role in T cell and NK cell exhaustion when bound to CD155 (Dougall et al, 2017 ; O'Donnell et al, 2019 ). Notably, TIGIT is highly expressed in CD8+T cells, CD4+T cells, and NK cells during tumor infiltration (Song et al, 2018 ; Josefsson et al, 2019 ; Lupo and Matosevic, 2020 ). In this study, we found that TIGIT was highly expressed in tumor tissues and that high TIGIT expression predicted a more advanced disease stage and worse prognosis in PSCCE.…”

Section: Discussionmentioning

confidence: 99%

CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus

Zhao

Feng

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

CD155/TIGIT overexpression has been detected in various human malignancies; however, its expression status in primary small cell carcinoma of the esophagus (PSCCE) and its prognostic significance remain unclear. In this study, we aimed to explore the expression and prognostic value of CD155 and TIGIT in PSCCE. We detected CD155 and TIGIT expression in 114 cases of PSCCE using immunohistochemistry (IHC) and evaluated their relationship with the clinicopathological characteristics and survival of the patients. Survival analyses were performed using the Kaplan-Meier method and Cox proportional hazards model. Nomogram performance was assessed via the concordance index (C-index) and calibration plots. Decision curve analysis (DCA) was performed to evaluate the net benefit of the nomogram. We found that CD155 and TIGIT were overexpressed in PSCCE tissues, CD155 expression correlated positively with TIGIT (p < 0.001) and was significantly associated with tumor size, T stage, distant metastasis, TNM stage, and Ki-67 score. TIGIT expression was also significantly associated with T stage, distant metastasis, and TNM stage. Patients with high CD155 and TIGIT expression had a significantly shorter overall survival (OS) and progression-free survival (PFS), while the multivariate model showed that CD155 expression and the therapeutic strategy are independent prognostic factors for PSCCE. In the validation step, OS was shown to be well-calibrated (C-index = 0.724), and a satisfactory clinical utility was proven by DCA. In conclusion, our findings revealed that CD155 and TIGIT are highly expressed in patients with PSCCE and are associated with shorter OS and PFS, supporting their role as prognostic biomarker.

show abstract

Section: Discussionmentioning

confidence: 99%

CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus

Zhao

Feng

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…This combination addresses several aspects of tumor immune evasion outcomes, namely tumor antigen heterogeneity, the immunosuppressive environment, and insufficient intratumoral NK cell presence ( , accessed on 1 March 2021). This procedure is applicable to other markers that are pro-tumorigenic, such as CD155 [ 94 ], and might offer possible treatment strategies for further investigations.…”

Section: Nk Cells As a Possible Immunotherapy Approach To Treat Glmentioning

confidence: 99%

Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells

et al. 2021

View full text Add to dashboard Cite

Immunotherapy has been established as an important area in the therapy of malignant diseases. Immunogenicity sufficient for immune recognition and subsequent elimination can be bypassed by tumors through altered and/or reduced expression levels of major histocompatibility complex class I (MHC I) molecules. Natural killer (NK) cells can eliminate tumor cells in a MHC I antigen presentation-independent manner by an array of activating and inhibitory receptors, which are promising candidates for immunotherapy. Here we summarize the latest findings in recognizing and regulating MHC I molecules that affect NK cell surveillance of glioblastoma cells.

show abstract

“…Although, the mechanism by which the CD226 receptors exert control over the function of NK cell is a challenge, the engagement of the receptor with CD155 in the transcription factor FOXO1 phosphorylation, which results in the inactivation of the receptor’s negative regulatory control over the effector function of NK cell. 226 , 240 …”

Section: Nk Cell As a Promising Therapeutic Target For Cancermentioning

confidence: 99%

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy

Cao

Wang

Jin

et al. 2020

Sig Transduct Target Ther

View full text Add to dashboard Cite

Recent studies have demonstrated the potential of natural killer (NK) cells in immunotherapy to treat multiple types of cancer. NK cells are innate lymphoid cells that play essential roles in tumor surveillance and control that efficiently kill the tumor and do not require the major histocompatibility complex. The discovery of the NK’s potential as a promising therapeutic target for cancer is a relief to oncologists as they face the challenge of increased chemo-resistant cancers. NK cells show great potential against solid and hematologic tumors and have progressively shown promise as a therapeutic target for cancer immunotherapy. The effector role of these cells is reliant on the balance of inhibitory and activating signals. Understanding the role of various immune checkpoint molecules in the exhaustion and impairment of NK cells when their inhibitory receptors are excessively expressed is particularly important in cancer immunotherapy studies and clinical implementation. Emerging immune checkpoint receptors and molecules have been found to mediate NK cell dysfunction in the tumor microenvironment; this has brought up the need to explore further additional NK cell-related immune checkpoints that may be exploited to enhance the immune response to refractory cancers. Accordingly, this review will focus on the recent findings concerning the roles of immune checkpoint molecules and receptors in the regulation of NK cell function, as well as their potential application in tumor immunotherapy.

show abstract

CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma

Cited by 73 publications

References 99 publications

CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus

CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus

Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy

Contact Info

Product

Resources

About